Cytokinetics Inc (CYTK)’s Ratio Roundup: Key Metrics for Trailing Twelve Months

Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.

As of close of business last night, Cytokinetics Inc’s stock clocked out at $57.89, down -6.78% from its previous closing price of $62.10. In other words, the price has decreased by -$6.78 from its previous closing price. On the day, 3.55 million shares were traded. CYTK stock price reached its highest trading level at $63.4573 during the session, while it also had its lowest trading level at $55.91.


To gain a deeper understanding of CYTK’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.19 and its Current Ratio is at 7.19.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on January 24, 2024, Downgraded its rating to Neutral and sets its target price to $92 from $61 previously.

On January 05, 2024, Morgan Stanley Downgraded its rating to Equal-Weight which previously was Overweight and also upped its target price recommendation from $60 to $90.

On November 09, 2023, Goldman started tracking the stock assigning a Buy rating and target price of $50.Goldman initiated its Buy rating on November 09, 2023, with a $50 target price.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 07 ’24 when Malik Fady Ibraham sold 15,547 shares for $65.11 per share. The transaction valued at 1,012,265 led to the insider holds 137,056 shares of the business.

HENDERSON JOHN T sold 10,562 shares of CYTK for $681,671 on Apr 25 ’24. The Director now owns 32,070 shares after completing the transaction at $64.54 per share. On Apr 09 ’24, another insider, Malik Fady Ibraham, who serves as the EVP Research & Development of the company, sold 32,605 shares for $74.31 each. As a result, the insider received 2,422,918 and left with 138,567 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 6069998080 and an Enterprise Value of 6205950464. For the stock, the TTM Price-to-Sale (P/S) ratio is 1614.44. Its current Enterprise Value per Revenue stands at 1654.038 whereas that against EBITDA is -12.78.

Stock Price History:

Over the past 52 weeks, CYTK has reached a high of $110.25, while it has fallen to a 52-week low of $25.98. The 50-Day Moving Average of the stock is -14.23%, while the 200-Day Moving Average is calculated to be 9.70%.

Shares Statistics:

It appears that CYTK traded 1.92M shares on average per day over the past three months and 1516970 shares per day over the past ten days. A total of 101.64M shares are outstanding, with a floating share count of 101.15M. Insiders hold about 3.27% of the company’s shares, while institutions hold 103.66% stake in the company. Shares short for CYTK as of 1714435200 were 13670662 with a Short Ratio of 7.12, compared to 1711584000 on 13228799. Therefore, it implies a Short% of Shares Outstanding of 13670662 and a Short% of Float of 21.39.

Most Popular

[the_ad id="945"]